- Home
- PMVP vs ALVR Comparison
PMVP vs ALVR Comparison
Compare PMVP & ALVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- ALVR
- Stock Information
- Founded
- PMVP 2013
- ALVR 2013
- Country
- PMVP United States
- ALVR United States
- Employees
- PMVP N/A
- ALVR N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PMVP Health Care
- ALVR Health Care
- Exchange
- PMVP Nasdaq
- ALVR Nasdaq
- Market Cap
- PMVP 85.5M
- ALVR 87.7M
- IPO Year
- PMVP 2020
- ALVR 2020
- Fundamental
- Price
- PMVP $1.65
- ALVR $0.90
- Analyst Decision
- PMVP Strong Buy
- ALVR Sell
- Analyst Count
- PMVP 4
- ALVR 5
- Target Price
- PMVP $5.75
- ALVR $1.00
- AVG Volume (30 Days)
- PMVP 185.0K
- ALVR 155.6K
- Earning Date
- PMVP 11-07-2024
- ALVR 11-04-2024
- Dividend Yield
- PMVP N/A
- ALVR N/A
- EPS Growth
- PMVP N/A
- ALVR N/A
- EPS
- PMVP N/A
- ALVR N/A
- Revenue
- PMVP N/A
- ALVR N/A
- Revenue This Year
- PMVP N/A
- ALVR N/A
- Revenue Next Year
- PMVP N/A
- ALVR N/A
- P/E Ratio
- PMVP N/A
- ALVR N/A
- Revenue Growth
- PMVP N/A
- ALVR N/A
- 52 Week Low
- PMVP $1.33
- ALVR $0.58
- 52 Week High
- PMVP $3.47
- ALVR $2.49
- Technical
- Relative Strength Index (RSI)
- PMVP 60.86
- ALVR 69.10
- Support Level
- PMVP $1.63
- ALVR $0.74
- Resistance Level
- PMVP $1.69
- ALVR $0.91
- Average True Range (ATR)
- PMVP 0.07
- ALVR 0.06
- MACD
- PMVP 0.01
- ALVR 0.01
- Stochastic Oscillator
- PMVP 52.65
- ALVR 94.50
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.